Skip to main content

Client News

Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment

26th November 2024

Pentixapharm Holding AG: First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

21st November 2024

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

20th November 2024

LINDIS Biotech Signs Licensing Agreement with Pharmanovia for the Commercialization of Catumaxomab

19th November 2024

Formycon Invites to Earnings Call on the Nine-Month Results 2024 and Announces Participation in International Investor Conferences

19th November 2024

Formycon Receives Positive CHMP Opinion for FYB203 (Aflibercept), a Biosimilar Candidate to Eylea® under the Tradenames AHZANTIVE® and Baiama®

18th November 2024

InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome

15th November 2024

Abivax Presents Third Quarter 2024 Key Financial Information

14th November 2024

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

14th November 2024

Andera Partners Continues its International Expansion and Announces the Opening of a Madrid Office

13th November 2024